Ghidul pentru managementul hipertensiunii arteriale 2007 Grupul ...

Revista Română de CardiologieVol. XXII, Nr. 3, 2007Ghidul pentru managementul hipertensiunii arteriale 2007Ghid al Societăţii Europene de Cardiologie734. Wing RR, Phelan S. Long-term weight loss maintenance. Am J ClinNutr 2005;82 (1 Suppl):222S-225S. RV.735. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, SevergniniB, Meani S, Magrini F, Zanchetti A. High prevalence of cardiacand extra-cardiac target organ damage in refractory hypertension. JHypertens 2001; 19:2063-2070. OS.736. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, NiroumandM, Leung RS, Bradley TD. High prevalence of unrecognized sleepapnoea in drug-resistant hypertension. J Hypertens 2001; 19:2271-2277. OS.737. Parati G, Ongaro G, Bonsignore MR, Glavina F, Di Rienzo M, ManciaG. Sleep apnoea and hypertension. Curr Opin Nephrol Hypertens2002; 11:201 214. RV.738. Narkiewicz K, Wolf J, Lopez-Jimenez F, Somers VK. Obstructive sleepapnea and hypertension. Curr Cardiol Rep 2005;7:435-440. RV.739. Baguet JP, Narkiewicz K, Mallion JM. Update on hypertension management:obstructive sleep apnea and hypertension. J Hypertens 2006;24:205-208. RV.740. Calhoun DA. Low-dose aldosterone blockade as a new treatmentparadigm for controlling resistant hypertension. J Clin Hypertens2007; 9(Suppl 1):19-24. RV.741. Saha C, Eckert GJ, Ambrosius WT, Chun TY, Wagner MA, ZhaoQ, Pratt JH. Improvement in blood pressure with inhibition of theepithelial sodium channel in blacks with hypertension. Hypertension2005;46:481-487. RT.742. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in managementof resistant hypertension: a surveillance study. J Hypertens2007;25:891-894. OS.743. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-reninstatus in therapy-resistant hypertension: a clue to efficient treatment. JHypertens 2004; 22:2217-2226. OS.744. de Leeuw PW, Kroon AA, Scheffers I, Tordoir J, Schmidli, MohauptM, Allemann Y, Jordan J, Engeli S, Liebeskind U, Luft FC, Eckert S,Hansky B, Kieval R, Cody R, Rossing M, Irwin E, Peters T. Baroreflexhypertension therapy with a cronically implanted system: preliminaryefficacy and safety results from the rheos debut-ht study in patientswith resistant hypertension. J Hypertens 2006; 24(Suppl 4):S300.(abstract).745. Isles CG. Malignant hypertension and hypertensive encephalophaty.In: Swales JD editor. Textbook of Hypertension. London: BlackwellScientific Publications; 1994. pp.1233-1248. RV.746. Davis BA, Crook JE, Vestal RE, Oates JA. Prevalence of renovascularhypertension in patients with grade III or IV hypertensive retinopathy.N Engl JMed 1979;301:1273-1276. OS.747. Lip GY, Beevers M, Beevers G. The failure of malignant hypertensionto decline: a survey of 24 years’ experience in a multiracial populationin England. J Hypertens 1994;12:1297-1305. OS.748. Giese J. Acute hypertensive vascular disease, 2: Studies on vascularreaction patterns and permeability changes by means of vital microscopyand colloidal tracer technique. Acta Pathol Microbiol Scand1964;62:497-515. OS.749. Kincaid-Smith P, McMichael J, Murphy EA. The clinical cause andpathology of hypertension with papilloedema. Quart J Med 1958;27:117-154. OS.750. Isles CG, Liu KG, Boulton-Jones M, Cameron H, Lever AF, MurrayG, Robertson JWK. Factors influencing mortality in malignant hypertension.J Hypertens 1985;3(Suppl 3):405-407. OS.751. Lip GY, Beevers M, Beevers DG. Complications and survival of 315patients with malignant-phase hypertension. J Hypertens 1995; 13:915-924. OS.752. Gotto AM Jr. Review of primary and secondary prevention trials withlovastatin, pravastatin, and simvastatin. Am J Cardiol 2005;96:34F-38F. RV.753. Clearfield M. Statins and the primary prevention of cardiovascularevents. Curr Atheroscler Rep 2006;8:390-396. RV.754. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primaryprevention of cardiovascular diseases with statin therapy: ameta-analysis of randomized controlled trials. Arch Intern Med 2006;166:2307-2313. MA.755. Gorelick PB, Schneck M, Berglund LF, Feinberg W, Goldstone J. Statusof lipids as a risk factor for stroke. Neuroepidemiology 1997;16:107-115. RV.756. Heart Protection Study Group. MRC/BHF Heart Protection Study ofcholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomised placebo-controlled trial. Lancet 2002;360:7-22. RT.757. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, CobbeSM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, MacfarlanePW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, SweeneyBJ, Twomey C, Westendorp RG. PROSPER study group. PROspectiveStudy of Pravastatin in the Elderly at Risk. Pravastatin in elderlyindividuals at risk of vascular disease (PROSPER): a randomisedcontrolled trial. Lancet 2002;360:1623-1630. RT.758. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, HennericiM, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM,Zivin JA. Stroke Prevention by Aggressive Reduction in CholesterolLevels (SPARCL) Investigators. High-dose atorvastatin after stroke ortransient ischemic attack. N Engl J Med 2006;355:549-559. RT.759. The ALLHAT Officers, Coordinators for the ALLHAT CollaborativeResearch Group. Major outcomes in moderately hypercholesterolemic,hypertensive patients randomized to pravastatin vs usual care. TheAntihypertensive and Lipid-Lowering Treatment to Prevent HeartAttack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007. RT.760. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, CaulfieldM, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J,Nieminen M, O’Brien E, Ostergren J. ASCOT investigators. The preventionof coronary events and stroke with atorvastatin in hypertensivesubjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA). Lancet 2003;361:1149-1158. RT.761. Borghi C, Dormi A, Veronesi M, Immordino V, Ambrosioni E. Useof lipid-lowering drugs and blood pressure control in patients witharterial hypertension. J Clin Hypertens 2002;4:277-285. RV.762. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, BergmanAJ, Alton KB. Ezetimibe: a review of its metabolism pharmacokineticsdrug interactions. Clin Pharmacokinet 2005;44:467-494. RV.763. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysisof randomised trials of antiplatelet therapy for prevention of death,myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. MA.764. Zanchetti A, Hansson L, Dahlof B, Julius S, Menard J, Warnold I,Wedel H. Benefit and harm of low-dose aspirin in well-treated hypertensivesat different baseline cardiovascular risk. J Hypertens 2002;20:2301-2307. CT.765. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L,Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. Aspirin and clopidogrelcompared with clopidogrel alone after recent ischaemic strokeor transient ischaemic attack in high-risk patients (MATCH): randomised,double-blind, placebo-controlled trial. Lancet 2004;364:331-337. RT.766. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE,Hennekens CH, Buring JE. A randomized trial of low-dose aspirin inthe primary prevention of cardiovascular disease in women. N Engl JMed 2005;352:1293-1304. RT.767. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primaryprevention of cardiovascular events: a summary of the evidencefor the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-172. MA.768. Wald NJ, Law MR. A strategy to reduce cardiovascular disease bymore than 80%. BMJ 2003;326:1419. RV.769. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE.Aspirin for primary prevention of coronary heart disease: safety andabsolute benefit related to coronary risk derived from meta-analysisof randomised trials. Heart 2001;85:265-271. MA.770. Zanchetti A, Hansson L, Leonetti G, Rahn KH, Ruilope L, WarnoldI, Wedel H. Low-dose aspirin does not interfere with the blood pressure-loweringeffects of antihypertensive therapy. J Hypertens 2002;20:1015-1022. RT.771. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortalityfrom coronary heart disease in subjects with type 2 diabetes and in